In the analysis of the PFI across these cancers, GTF2E2 was associated with an increased risk in ACC, LGG, KICH, KIRC, KIRP, LIHC, MESO and PAAD (Fig 5, Fig S3A–S3L). Here, GTF2E2 is linked to cancer.